- Sorted by date
- Hybrid Sort
- Smart Random Sort
- Sort by relevance
Advertisements
» Related Searches: prostate cancer, Prostate Cancer, cancer prostate, late prostate cancer, cancers prostate
Results 41 to 50 of 54 
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic …
- ├ Fusion Prostate Cancer: An Early Molecular Event … — ScienceDaily Headlines
- ├ Scientists Design A PSA-activated Protoxin That Kills … — Health News from Medical News Today
- ├ Aeterna prostate cancer drug shows promise — Pharmaceutical Business Review Latest News
- └ all 10 related »
First responders' toxic risks
A University of Cincinnati study shows that firefighters are much more likely to develop
non-Hodgkins lymphoma, multiple myeloma, and testicular or prostate cancer … 
- ├ Adolescents, risks and the pitfalls of rationality — EurekAlert! - Medicine and Health
- ├ 'Toxic waste' prisoners attacked — BBC News | News Front Page | World Edition
- ├ Landfill poses toxic threat. — Environmental Health News
- └ all 10 related »
Aeterna prostate cancer drug shows promise
Aeterna Zentaris has presented detailed positive phase II results in hormone-dependent,
inoperable prostate cancer for its compound ozarelix …
- ├ Dendreon completes FDA filing for prostate-cancer drug … — The Seattle Times: Horse racing
- ├ Recurrent breast cancer: Drug shows promise — The Cancer Blog
- ├ A transmission electron micrograph shows a prostate … — Top Stories Photos - Reuters on Yahoo! News Photos
- └ all 10 related »
Dendreon Asks FDA to OK Prostate Drug
Cancer-treatment developer Dendreon said it submitted the final portion of a biologics
license application to the FDA …
- ├ Dendreon Completes Submission of Biologics License Application … — Government/ Industry Regulation News from StratCenter.com …
- ├ Dendreon seeks OK for Provenge — United Press International - Health Business
- ├ FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- └ all 10 related »
Dendreon Completes Submission of Biologics License Application to FDA for …
Dendreon Corp announced that the final portion of the Biologics License Application for
PROVENGE has been electronically submitted to the US FDA, which completes its rolling
submission that began in …
- ├ Scientists Discover Way To Block Growth Of … — Health News from Medical News Today
- ├ FDA Grants Priority Review for Soliris BLA … — StratWire - Business of Healthcare NewsFeed
- ├ ReGen Biologics Announces Results of FDA Appeal — Government/ Industry Regulation News from StratCenter.com …
- └ all 10 related »
Dendreon completes FDA filing for prostate-cancer drug
Dendreon said Monday it has submitted the final portion of its application to the Food and
Drug Administration for approval to market its prostate cancer drug in the U.S …
- ├ Prostate-specific symptoms of prostate cancer in a … — Prostate Cancer and Prostatic Diseases
- ├ 'Muscle' Protein Drives Prostate Cancer — Health News from Medical News Today
- ├ Elderly, ill men get unneeded prostate cancer … — EurekAlert! - Policy and Ethics
- └ all 10 related »
In Memoriam: Edwin Bell (1924-2006)
… prostate cancer. Treatment started and he returned home just over a week later.
After a number of doctor visits and tests, it became apparent that the condition was
terminal. After …
- ├ Tatum Bell to start; M. Bell out? — NFL Player News : CBS SportsLine.com
- ├ Bell / Agusta Bell 412 - Medium … — Aerospace Technology
- ├ Mike Bell inactive — NFL Player News : CBS SportsLine.com
- └ all 10 related »
Effect of Akt inhibition on scatter factor-regulated gene expression in …
- ├ Scientists Design A PSA-Activated Protoxin That Kills … — Health News from Medical News Today
- ├ [Genetics] Small dsRNAs induce transcriptional activation in … — Proceedings of the National Academy of Sciences …
- ├ The Evolving Role of Angiogenesis Inhibition in … — Medscape Pathology Headlines
- └ all 10 related »
Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion …
The presence of a gene fusion in prostate tumors is significantly associated with
aggressive cancer, metastatic spread, and an increased probability of death, a team of
researchers is reporting …
- ├ Two Markers Strongly Linked To Prostate Cancer … — ScienceDaily Headlines
- ├ Study questions radiation for prostate (Associated Press) … — Yahoo! Health: Health News
- └ all 10 related »
Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress …
Professor Frans M.J. Debruyne, Chairman of the Department of Urology, University Medical
Center in Nijmegen, The Netherlands to Present Ozarelix Phase 2 Prostate Cancer Data …
- ├ Spectrum Pharmaceuticals wird auf dem Kongress der … — Presseportal.de Finanzen
- ├ - Webcast Alert: Isis Pharmaceuticals Announces Its … — Partnerships/ Joint Ventures News from StratCenter.com …
- ├ Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase … — Nephrology/ Dialysis News from StratCenter.com
- └ all 10 related »